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Agenda 
• Speaker Background 
• Broad overview of medical and 
pharmaceutical research 
• Commercialization Support at GT 
• Enterprise Innovation Institute 
• ATDC and VentureLab 
• VentureLab Process 
• Questions & Answers 
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Harold H. Shlevin, PhD 
• 25+ years leadership experience in pharma, 
      medical devices & vaccines companies. 
 Strong background in R&D through commercial 
operations 
• CEO Solvay Pharmaceuticals, Inc. 
• Founder  & CEO Tikvah Therapeutics, Inc. 
• Founder  & SVP CIBA Vision Ophthalmics 
• 18+ years with Ciba Geigy Pharmaceuticals 
in various positions of increasing 
responsibility 
• Ph.D., Univ. of Rochester Medical School 
• Postdoc. - Mayo Clinic 
• Assistant Professor – Mayo Medical School 
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Importance of Patents to  
Pharmaceutical Innovation 





Would NOT have 
been Developed 
Pharmaceuticals 65 65 
Chemicals 30 38 
Petroleum 18 25 
Machinery 15 17 
Electrical Equipment 1 11 
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Sources: Innovation.org, Great Moments in Innovation,  http://www.innovation.org/index.cfm/nonav/Great_Moments_in_Innovation; NIH, 
National Institute of Allergy and Infectious Disease, Tuberculosis (TB), Age of Optimism, 
http://www3.niaid.nih.gov/topics/tuberculosis/Research/researchFeatures/history/historical_optimism.htm. 
1980s – 2000 1950s – 1970s 1900s – 1940s 
1930s & 1940s 
1932 – First antibiotic (sulfa 
drugs) 
1935 – Discovery of cortisone            
1938 – First epilepsy Rx 
1948 – First chemotherapy Rxs 
1960s & 1970s 
1963 – Measles vaccine 
1967 – First beta blocker  
1968 – First anti-rejection medicines  
          for organ transplants 
1972 – Advances in anesthesia 
1977 – First non-surgical treatment  
    for ulcers 
1978 – First biotech product 
          (synthetic human insulin) 
1990s 
1993 – First Alzheimer’s Rx 
1994 – New breast cancer Rx 
         - Polio eradicated in the  
           Americas 
1995 – AIDS Rx advance 
(HAART) 
1995–97 – Four new classes  
                of oral diabetes Rxs 
1997–98 – Advance in                    
                Parkinson’s Therapies 
1900–1929 
1900 – U.S. life expectancy is 45 
1908 – Tuberculosis vaccine 
1922 – Insulin for diabetes 
1924  – Tetanus vaccine 
1928 – Discovery of penicillin 
1950s 
1950 – Discovery of prednisone 
1951 – First Rx for depression 
1953 – First leukemia Rx 
1954 – Polio vaccine 
1958 – First diuretic to treat high  
           blood pressure 
1980s 
1981 – First ACE inhibitor to treat  
           high blood pressure 
1986 – First monoclonal antibody                  
           treatment 
1987 – New class of depression  
           medicines (SSRIs) 
         – First AIDS Rx 
        – First statins to lower  
           cholesterol 
Selected Advances in the  
20th Century 
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*Note: “Other” includes medical care provided  by private employers for employees at their work site, government spending 
for non-specified medical care by service usually delivered in schools, military field stations, and community centers. 
 



































Number of Compounds in Development, by Region,* 
1997–20091 
*Note: Reflects the number of compounds in clinical trials or awaiting approval as of June of each year. Compounds in 
development for multiple regions are counted in each region for which regulatory approval is sought, and multiple 
indications are counted only once. 
Sources: 1Adis R&D Insight, Custom data run, February 2009, January 2010; 2G. Verheugen, “Address to the Concluding 
Session of the European Track” (Lyon) 2005. 
…in the late 1980s only 41% 
of the top 50 innovative 
drugs were of American 
origin, in the late 1990s…[it 
had] climbed to 62%....   
 
In 1990, the pharmaceutical 
industry spent 50% more on 
research in Europe than in 
the U.S.  In 2001, the 
situation was reversed with 
40% more spent in the U.S.2 
 
–Gunter Verheugen, Vice-
President of the European 
Commission for Enterprise 
and Industry 
Medical Research in the U.S.  
Outpaces the Rest Of the World 
Sources: Drug Discovery and Development: Understanding the R&D Process, www.innovation.org; CBO, Research and 
Development in the Pharmaceutical Industry, 2006. 
Developing a new medicine takes an average of 10–15 years; the Congressional 
Budget Office reports that “relatively few drugs survive the clinical trial process”   
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Drug Development Takes Longer 
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“Ensure that innovation, entrepreneurship, 
& public service are fundamental 
characteristics of our graduates” 
• Innovate in how we incentivize & support 
commercialization 
• “GT will encourage & reward faculty 
innovation & entrepreneurship in all 
their manifestations…” 
• “GT will continue to develop the 
infrastructure that will enable our faculty 
to perform at the highest levels, from 
idea generation to commercialization…” 




Georgia Tech Strategic Plan & Vision 
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Stephen E. Cross, PhD
Exec. VP - Research
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• Some space 
     VentureLab today 
• Focused on GT 
• Commercialization of 
GT inventions 
• Catalyst coaching & 
partnering 
• Industry expertise 
• Experts in starting and 
managing small new 
companies 
• Partner with inventors 
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In brief,  VentureLab . . . Partners 
with Faculty for Technology 
Development 
• Provides comprehensive assistance to faculty 
members, research staff members and 
graduate students who want to commercialize 
the technology innovations they have 
developed.  
• Supports faculty in a consultant-like role 
related to commercialization 
• Ourselves or through our network 
• View research ideas as a “valley of 
opportunity”; leverages research investment 
• Goals:  Products 
• Successful startup companies  





• Founded September 2001 
• Now a model for other universities 
• Part of Enterprise Innovation Institute (EI2) 
• Reports up through Office of the VP of 
Research 
• Staff has substantial private-sector experience 
• Faculty-focused process  
• Risk identification and mitigation 
• Fundable innovations 
• Saying no and why, as appropriate 
• Education 
 
• Goal: Products based on Georgia Tech research 
and its collaborative partners  
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Inventive capacity of Georgia Tech 
is enormous 
• Invention disclosures ~400 (*) 
• Startup ideas    ~250 
• License ideas   ~200 
 
• Value is realized as PRODUCTs 
which leverage the research 
investments 
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Sources: 1Burrill & Company, analysis for PhRMA, 2010 (Includes PhRMA research associates and nonmembers) in 
PhRMA, “Profile 2010, Pharmaceutical Industry;” PhRMA, “PhRMA Annual Membership Survey,” 2010; 2Adapted from E. 
Zerhouni, Presentation at Transforming Health: Fulfilling the Promise of Research, 2007; 3NIH Office of the Budget, 
“Natiional Institutes of Health: Enacted Appropriations for FY 2008-FY 2010,” 
http://officeofbudget.od.nih.gov/pdfs/FY11/FY%202010%20Enacted%20Appropriations.pdf.  
There is an ecosystem 
of science and 




FDA, all of this is an 
ecosystem that is 
envied in the rest of 
the world. 
  
– E. Zerhouni,  
Director of NIH 











NIH – $31.2B3 
Government and biopharmaceutical industry research are complementary 
Federal & Industry Roles in  
Research and Development 
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• Two-way street toward understanding and 
alignment 
• Invention 
• Path to commercialization 
• Science is critical to attract greater 
business interest 
• Business aspects (market, milestones, 
meetings, management & money) 
• Risk identification & mitigation 
• Product Development 
• Business Development 






• Become aware of potential opportunities 
early in the research process 
• viz., well before the traditional invention 
disclosure is considered 
• A lot of good ideas stay undeveloped 
• Little tweaks can often better define the 
commercial potential 
• Active process 
• Commercialization takes time & 
requires capital 
• Internally driven by industry experts 
• Operate across other translational 





Access to Technology 











     iterative  
     continuous  
     builds value 
Early commercial 
insight can help 
build significant 
value or kill a project 
early 
Feedback to 












Georgia Tech Invention Disclosure & 
Licensing Process are Multi-Factorial 
Rights to 
Faculty? 
VentureLab Tech. Marketing 
Path? 


































Part 1 of 3+ parts 
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Source:  GTRC website   www.gtrc.gatech.edu 
Invention Disclosures 
Are NOT 



















Message to Faculty/Inventors… 
Business 
Realities Money Technology Concept 
A  
Company 
Lots of good ideas stay 
undeveloped 
- Commercialization 
takes time and requires 
capital 
Key Success Factors 
- Technology 
- Versatile core team 
- Market entry strategy 
- Product development 
strategy 
- Money 














Opportunities from the “Valley” 
• Return from exceptional startups 
• Return from all startups 
• Return from Proof of Concept Companies 











• Classic startup questions—Who, What, 
Where, When, Why, How: 
• Who is the customer? 
• What is the pain they are trying to 
eliminate? 
• Who/What will pay for the product? 
• Why is your technology the right answer? 
• When will effective competition emerge?  
• What are the growth trends?  
• Product Development Plan & Costs 
• Who are potential partners?  
• Exits ? 
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Business Plan 
• It’s far too easy to focus on the technology 
promise, and ignore the “details”: 
• When will you have a prototype? 
• When will you have a paying 
customer? 
• How many people do you need to 
hire? 
• How much money do you need at 
first?  
• When does that run out? 
• How much will you need after that? 
• How do you know when you are 
winning? 28 
•Assistance with small-
business grants from eleven 
Federal agencies. 
 
•Grants and loans to startups 
based on Georgia university 
research. 
 
•Equity investments in 
startups with a connection to 
Georgia Tech. 
 
Early Stage Funding 
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One-Stop Center for Technology 
Development & Commercialization 
• Clear pathway from laboratory innovation to the 
commercial market 
• VentureLab specialists help faculty transform 
innovations into early-stage companies / licenses 
• Assist in product development plan, 
• Assist in business plan development, 
• Assist in connecting the innovators with experienced 
entrepreneurs, partners, etc., 
• Assist in locating sources of early-stage financing 
and preparing the new companies for the business 
world, 
• Wet-lab space in an on-campus incubator 
• Experienced industry experts guiding the processes and 
educating  
• Saying “no” and why, when appropriate 
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“Research is the 
transformation of 
money into knowledge.  
Innovation is the 
transformation of 
knowledge into money.”  
Geoff Nicholson,  Ph.D. 
(Post-it® note inventor) 









• Founded September 2001 
• Now a model for other universities 
• Part of Enterprise Innovation Institute (EI2) 
• Reports up through Office of the VP of Research 
• Staff has substantial private-sector experience 
• Faculty-focused process  
• Risk identification and mitigation 
• Venture-backable innovations 
 
• Goal: Successful startup companies based on Georgia 
Tech research 
• Successful commercialization 33 
Background 
• ATDC is ~30 years old (estb. 1980) 
• VentureLab was established in 2001 
• In 2009,  
• ATDC was opened up to the 
community of entrepreneurs across 
the State 
• VentureLab was merged into ATDC 
• July 2011 – VentureLab was separated 
from ATDC … 
• Better focus on commercialization of 
Georgia Tech related inventions 
• Consistent with Gtech’s strategic 




• Startups are very high risk 
• GT startups are a bit less 
high risk  
• Equity in early rounds   
• Return  
 Equity on sale  
  Royalty/Milestones 
               from license 
  
• Successful License 
    
1/3 to inventors 
1/3 to department 
1/3 to Georgia Tech 
Failure rates ~ 90% 
Failure rates ~ 70% 
Later dilution 
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2009 ATDC Serving the Georgia 
Entrepreneurial Community 
Community Startups  
• Explosive Growth 
• ~ 450 companies 
• + 3 to 5 per week 
• Services 
• Educational programs 
• Incubation space 
• Outreach circles 
• Mentoring 
• Catalyst coaching 
• Outward Facing 
 
University Start Ups 
• Everything  
• GRA funding 






• Inward Facing 
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